FENNEC PHARMACEUTICALS

Company snapshot

Fiercely dedicated to the fight against cisplatin-induced ototoxicity. www.fennecpharma.com

• 2 approved product(s) across US/EU regulatory metadata.
• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for FENNEC PHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for FENNEC PHARMACEUTICALS.

1. May 23, 2026 Clinical update

   Pedmark® STS — Phase 2

2. May 27, 2025 Patent grant

   Therapeutic uses for sodium thiosulfate formulations

3. Jun 4, 2024 Patent grant

   Therapeutic uses for sodium thiosulfate formulations

4. May 28, 2024 Patent grant

   Therapeutic uses for sodium thiosulfate and formulations

5. Apr 23, 2024 Patent grant

   Therapeutic uses for sodium thiosulfate formulations

View all clinical trial activity →

• What is FENNEC PHARMACEUTICALS?

  FENNEC PHARMACEUTICALS is a biotech organization headquartered in Research Triangle Park, USA. It trades on NYSE under ticker FENC. Primary therapeutic focus areas include Solid Tumor Malignancies. NovaPharmaNews links 1 clinical program(s), 1 drug profile(s), and 8 patent record

• Is FENNEC PHARMACEUTICALS publicly traded?

  Yes. FENNEC PHARMACEUTICALS is listed with ticker FENC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does FENNEC PHARMACEUTICALS develop or market?

  We link 1 drug profile(s) where FENNEC PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/fennec-pharmaceuticals-inc#company-drugs.

• What are the latest developments for FENNEC PHARMACEUTICALS?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does FENNEC PHARMACEUTICALS focus on?

  FENNEC PHARMACEUTICALS focuses on Solid Tumor Malignancies based on our analysis of their pipeline programs and drug development activities.